Side-by-side · Research reference

5-Amino-1MQvsGlutathione

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongAUTO-DRAFTED8/38 cited

BHuman-MechanisticHUMAN-REVIEWED6/39 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

Glutathione

Endogenous Tripeptide · Antioxidant

γ-Glu-Cys-GlyStructure

UbiquitousTissue distribution

GCL + GSBiosynthesisWang 2026 Aiana 2026

IV · Oral · Inhaled

01Mechanism of Action

Parameter

5-Amino-1MQ

Glutathione

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

Intracellular redox systems, glutathione peroxidase, glutathione transferase

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction

Feedback intact?

—

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025 Hecht 2026

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

Glutathione

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

—

Frequency

Once daily, fasted

—

Lower / starter dose

50 mg / day

—

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Animal mechanistic + human mechanistic

Duration

8–12 weeks per cycle

—

Form

Oral capsule

—

Timing

Morning fasted preferred

—

Half-life

Hours (estimated; no human PK published)

—

Endogenous synthesis

—

Hepatic synthesis ~10 g/day (basal rate)

Tissue-specific; demand-driven upregulation via Nrf2 signaling.

Exogenous oral

—

250–1000 mg/day

Bioavailability limited; gastric hydrolysis reduces systemic uptake.

IV supplementation

—

600–1200 mg (research protocols)

Used in clinical oxidative stress and hepatic detoxification studies.

Precursor strategy

—

N-acetylcysteine (NAC) 600–1200 mg/day

Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.

04Side Effects & Safety

Parameter

5-Amino-1MQ

Glutathione

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

—

Pregnancy / OB

Avoid

—

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Oral supplementation

—

GI discomfort, bloating (mild, dose-dependent)

IV administration

—

Rare hypersensitivity, infusion site reaction

Inhalation

—

Bronchospasm risk in asthma (rare)

Tumor metabolism

—

Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

Glutathione

—

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

Glutathione

·Active malignancy (theoretical cysteine supply risk)Hecht 2026
·Severe asthma (inhaled formulations)

05Administration Protocol

Parameter

5-Amino-1MQ

Glutathione

1. Form

Oral capsule. No injection.

Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.

2. Administration

Take with water, fasted preferred.

Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.

3. Timing

Morning fasted.

Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.

4. Storage

Room temp ≤25 °C, dry place.

N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.

5. Caveat

Monitor B-vitamin status with chronic use.

—